Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs QUALCOMM, Inc. (QCOM) Price & Performance

Merck & Co., Inc.Trade
QUALCOMM, Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs QUALCOMM, Inc. — how do they compare? Merck & Co., Inc. trades at $130.21 (market cap $323.00B), while QUALCOMM, Inc. trades at $163.62 (market cap $170.28B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

MRKQCOM
Market Cap
$323.00B$170.28B
Sector
HealthTechnology
52-Week High
$131.84$251.10
52-Week Low
$77.60$124.07
Enterprise Value
$369.77B$177.24B
Dividend Yield
2.6%2.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

QUALCOMM, Inc.

Qualcomm (QCOM) trades at $162.68, down 3.09% amid broader semiconductor sector pressure. The stock shows mixed signals with bearish technical indicators but strong fundamentals including recent earnings beats and a 21.01% net income margin. Recent news highlights Qualcomm's strategic pivot toward AI and data centers, though competition from Nvidia's new PC chip has sparked investor concerns. The company maintains solid cash flow generation of $14.01B from operations in 2025 and continues dividend payments.

Qualcomm presents a compelling value opportunity with a P/E of 18.53 below sector averages, supported by analyst consensus price target of $200.56 implying 23% upside. Key risks include smartphone market softness and intensifying AI competition. The company's diversification into automotive and data centers provides growth catalysts, though execution risks remain. Current levels offer attractive entry for long-term investors seeking exposure to semiconductor and AI infrastructure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About QUALCOMM, Inc.

Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.

Read more on QCOM